Blockbuster hopes grow for Celgene-partnered asset

Celgene (Nasdaq: CELG) has provided cause for celebration for Bristol-Myers Squibb (NYSE: BMY), which is set to take over the US biotech company, and its partner Acceleron Pharma (Nasdaq: XLRN).

The US Food and Drug Administration (FDA) has accepted reviews for the use of luspatercept in patients experiencing sickness who need red blood cell transfusions with both myelodysplastic syndromes and beta-thalassemia.

In the latter indication, the FDA has granted priority review to the application, and the agency has set a Prescription Drug User Fee Act (PDUFA) date of December 4. The PDUFA date for the MDS indication is April 4, 2020.